Trial Profile
A Multi-Institutional, Single Arm, Two-Stage Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- 25 May 2018 Status changed from active, no longer recruiting to completed.
- 06 Jul 2017 Planned End Date changed from 1 Sep 2017 to 1 Mar 2018.
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.